Product image of Mayzent (Siponimod) supplied by GNH India

Mayzent

Active Ingredient:
Siponimod
Origin:
EU

Mayzent (Siponimod)

Siponimod, the active ingredient in Mayzent, is a sphingosine‑1‑phosphate (S1P) receptor modulator presented as an oral tablet for oral use. It treats relapsing forms of multiple sclerosis, including secondary progressive multiple sclerosis, in adults.

GNH India supplies Mayzent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Novartis Europharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mayzent (siponimod) is used in the management of relapsing multiple sclerosis, a disease characterized by immune‑mediated central nervous system inflammation.

  • Relapsing‑remitting multiple sclerosis: reduces the frequency of clinical relapses and slows disability progression.
  • Secondary progressive multiple sclerosis with active disease: decreases relapse rate and may delay worsening of disability.
  • Active disease in adults with multiple sclerosis: limits new inflammatory lesions and improves MRI outcomes.

How It Works

  • Siponimod selectively binds to sphingosine‑1‑phosphate receptors S1P1 and S1P5 on lymphocytes, preventing their egress from lymph nodes. This reduces circulating lymphocyte numbers, limiting immune‑mediated inflammation within the central nervous system and thereby modifying disease activity in multiple sclerosis.

Side Effects

Siponimod may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Headache: mild to moderate pain in the head.
  • Upper respiratory tract infection: symptoms such as sore throat or nasal congestion.
  • Elevated liver enzymes: increase in ALT or AST observed in laboratory tests.
  • Hypertension: rise in blood pressure measured during routine monitoring.

Serious or Rare Side Effects

  • Severe infections: opportunistic infections including fungal or viral pathogens.
  • Cardiac conduction abnormalities: bradycardia or atrioventricular block.
  • Macular edema: swelling of the central retina that may affect vision.

Precautions & Warnings

When prescribing siponimod, clinicians should consider several safety precautions.

  • Baseline cardiac assessment: perform ECG and monitor heart rate before initiating therapy.
  • Lymphocyte count monitoring: check absolute lymphocyte levels regularly to detect lymphopenia.
  • Liver function testing: assess ALT/AST at baseline and periodically during treatment.
  • Vaccination status: ensure patients are up‑to‑date with live vaccines before starting.
  • Pregnancy and breastfeeding: avoid use in pregnant or nursing women unless benefits outweigh risks.
  • Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Avoid Interactions

Siponimod can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • CYP3A4 strong inhibitors: co‑administration may increase siponimod exposure and risk of toxicity.
  • CYP3A4 strong inducers: may reduce siponimod levels, decreasing therapeutic effect.
  • Live attenuated vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

  • Antihypertensive agents: siponimod may enhance blood‑pressure‑lowering effects.
  • Other immunosuppressants: combined use can increase infection risk.
  • QT‑prolonging drugs: monitor cardiac rhythm as additive effects are possible.

Frequently Asked Questions

Mayzent is indicated for the treatment of relapsing forms of multiple sclerosis, including secondary progressive multiple sclerosis with active disease. It helps reduce the frequency of clinical relapses and may slow the progression of disability in adult patients.

Siponimod selectively modulates sphingosine‑1‑phosphate receptors S1P1 and S1P5 on lymphocytes. By blocking these receptors, it prevents lymphocytes from leaving lymph nodes, thereby lowering the number of circulating immune cells that can enter the central nervous system and cause inflammation.

The dose of Mayzent is individualized by the prescribing clinician based on the patient’s medical condition, weight, and tolerability. The prescriber determines the appropriate starting dose and any subsequent titration according to approved labeling and clinical guidelines.

Safety of siponimod in pregnancy and lactation has not been established. It is generally advised to avoid use during pregnancy and breastfeeding unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a healthcare professional is essential.

To order Mayzent, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mayzent (siponimod) and fingolimod belong to the same class of S1P receptor modulators but differ in receptor selectivity and pharmacokinetic profile. Siponimod selectively targets S1P1 and S1P5, which may offer a different safety and efficacy balance, particularly in secondary progressive MS, while fingolimod has broader S1P receptor activity.

Mayzent tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in extreme heat or humidity to maintain product stability.

Mayzent is taken orally as a tablet, usually once daily. The tablet should be swallowed whole with water and can be taken with or without food, following the dosing schedule prescribed by the treating physician.

Serious risks include severe infections, cardiac conduction abnormalities such as bradycardia or AV block, and macular edema that can affect vision. Patients should be monitored regularly for signs of infection, cardiac changes, and eye symptoms, and any concerning findings should be reported promptly.

Mayzent should not be used in patients with known hypersensitivity to siponimod or any of its excipients, those with certain cardiac conditions that predispose to conduction problems, or individuals who are pregnant or breastfeeding unless the benefits outweigh the risks. A thorough medical assessment is required before initiation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Siponimod

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT